Hillary Clinton All Bark, No Bite with Biotech Tweet
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Market Reaction to Clinton Proposals Seen as 'Premature' and 'Overdone' - TD Securities (VRX)
September 23, 2015 11:42 AM EDTTD Securities maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $300. Analyst Lennox Gibbs called the market's reaction to proposals from presidential candidate Hillary Clinton premature and overdone.
Gibbs views plans to authorize Medicare to negotiate prices with drug manufacturers as the most noteworthy of Clinton's proposals, and he pointed out that Valeant derives an estimated 1520% of its revenues from Medicare.
"Drug stocks are down 3% since... More
Hillary Clinton Tweet Doesn't Change Bullish View on Valeant Pharmaceuticals (VRX), BMO Capital Says
September 21, 2015 1:57 PM EDTBMO Capital analyst Alex Arfaei weighed in on Valeant Pharmaceuticals (NYSE: VRX) which is down 6% in response to a Tweet from Hillary Clinton referring to this article in the... More
UPDATE: Biotech Bounces Off Lows (IBB)
September 21, 2015 1:19 PM EDT(Updated - September 21, 2015 1:29 PM EDT)
Biotech stocks bounced off lows Monday afternoon, paring declines that were largely driven by fears of increased government regulation of drug pricing. The source of concern was a tweet by presidential candidate Hillary Clinton... More

